Cellular and molecular basis for acute nongenomically mediated actions of SERMs

Selective Estrogen Receptor Modulators: A New Brand of Multitarget Drugs

Volumn , Issue , 2006, Pages 79-102

  Díaz, Mario ^a   Marrero Alonso, Jorge ^a   García Marrero, Benito ^a,b   Marín, Raquel ^a   Gomez, Tomás ^a   Alonso, Rafael ^a  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

^b INSTITUTO DE PRODUCTOS NATURALES Y AGROBIOLOGÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954848216     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/3-540-34742-9_4     Document Type: Chapter

References (117)

1. Ahn SJ, Yoon MS, Hyuk S, Han W, Yoon YD, Han JS, Noh DY (2003) Phospholipase C-protein kinase C mediated phospholipase D activation pathway is involved in tamoxifen induced apoptosis. J Cell Biochem 89(3):520-528
2. Allen MC, Gale PA, Hunter AC, Lloyd A, Hardy SP (2000) Membrane impermeant antioestrogens discriminate between ligand- and voltage-gated cation channels in NG108-15 cells. Biochim Biophys Acta 1509(1-2):229-236
3. Allen MC, Newland C, Valverde MA, Hardy SP (1998) Inhibition of ligand-gated cationselective channels by tamoxifen. Eur J Pharmacol 354(2-3):261-269
4. Al-Shawi MK, Polar MK, Omote H, Figler RA (2003) Transition state analysis of the coupling of drug transport to ATP hydrolysis by P-glycoprotein. J Biol Chem 278(52):52629-52640
5. Arteaga E, Villaseca P, Bianchi M, Rojas A, Marshall G (2003) Raloxifene is a better antioxidant of low-density lipoprotein than estradiol or tamoxifen in postmenopausal women in vitro. Menopause 10(2):142-146
6. Batra S (1990) Interaction of antiestrogens with binding sites for muscarinic cholinergic drugs and calcium channel blockers in cell membranes. Cancer Chemother Pharmacol 26:310-312
7. Ben-Baruch G, Schreiber G, Sokolovsky M (1982) Cooperativity pattern in the interaction of the antiestrogen drug clomiphene with the muscarinic receptors. Mol Pharmacol 21:287-293
8. Berman E, McBride M, Tong W (1994) Comparative activity of tamoxifen and N-desmethyltamoxifen in human multidrug resistant leukemia cell lines. Leukemia 8(7):1191-1196
9. Borras M, Jin L, Bouhoute A, Legros N, Leclerck G (1994) Evaluation of estrogen receptor, antiestrogen binding sites and calmodulin for antiestrogen resistance of two clones derived from the MCF-7 breast cancer cell line. Biochem Pharmacol 48:2015-2024
10. Boyan BD, Sylvia VL, Frambach T, Lohmann CH, Dietl J, Dean DD, Schwartz Z (2003) Estrogen-dependent rapid activation of protein kinase C in estrogen receptor-positive MCF-7 breast cancer cells and estrogen receptor-negative HCC38 cells is membranemediated and inhibited by tamoxifen. Endocrinology 144(5):1812-1824
11. Brandes LJ, Bogdanovic RP, Cawker MD, La Bella FS (1987) Histamine and growth: interaction of antiestrogen binding site ligands with a novel histamine site that may be associated with calcium channels. Cancer Res 47(15):4025-4031
12. Brandt S, Heller H, Schuster KD, Grote J (2004) Tamoxifen induces suppression of cell viability and apoptosis in the human hepatoblastoma cell line HepG2 via downregulation of telomerase activity. Liver Int 24(1):46-54
13. Braybrooke JP, Vallis KA, Houlbrook S, Rockett H, Ellmen J, Anttila M, Ganesan TS, Harris AL, Talbot DC (2000) Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine. Cancer Chemother Pharmacol 46(1):27-34
14. Cabot MC, Zhang Z, Cao H, Lavie Y, Giuliano AE, Han TY, Jones RC (1997) Tamoxifen activates cellular phospholipase C and D and elicits protein kinase C translocation. Int J Cancer 70(5):567-574
15. Cantabrana B, Hidalgo A (1992) Effects of nonsteroidal antiestrogens in the in vitro rat uterus. Pharmacology 45:329-337
16. Caponigro F, French RC, Kaye SB (1997) Protein kinase C: a worthwhile target for anticancer drugs? Anticancer drugs 8:26-33
17. Caroni P, Carafoli E (1981) Regulation of Ca2+-pumping ATPase of heart sarcolemma by a phosphorylation-dephosphorylation process. J Biol Chem 256:3262-3270
18. Chan Y, Leung F, Yao X, Lau C, Vanhoutte PM, Huang Y (2004) Raloxifene relaxes rat pulmonary arteries and veins: roles of gender, endothelium and antagonism of Ca2+ influx. J Pharmacol Exp Therap
19. Chatterjee M, Harris AL (1990) Reversal of acquired resistance to adriamycin in CHO cells by tamoxifen and 4-hydroxy tamoxifen: role of drug interaction with alpha 1 acid glycoprotein. Br J Cancer 62(5):712-717
20. Cho SY, Kim JH, Paik YK (1998) Cholesterol biosynthesis from lanosterol: differential inhibition of sterol delta 8-isomerase and other lanosterol-converting enzymes by tamoxifen. Mol Cells 8(2):233-239
21. Christopher TA, Lopez BL, Stillwagon JC, Gao F, Gao E, Ma XL, Ohlstein EH, Yue TL (2002) Idoxifene causesendothelium-dependent, nitric oxide-mediatedvasorelaxation in male rats. Eur J Pharmacol 446(1-3):139-143
22. Custodio JB, Almeida LM, Madeira VM (1993) The active metabolitehydroxytamoxifen of the anticancer drug tamoxifen induces structural changes in membranes. Biochim Biophys Acta 1153(2):308-314
23. Da Costa LS, De Oliveira MA, Rubim VS, Wajngarten M, Aldrighi JM, Rosano GM, Neto CD, Gebara OC (2004) Effects of hormone replacement therapy or raloxifene on ambulatory blood pressure and arterial stiffness in treated hypertensive postmenopausal women. Am J Cardiol 94(11):1453-1456
24. De Medina P, Favre G, Poirot M (2004a) Multiple targeting by the antitumor drug tamoxifen: a structure-activity study. Curr Med Chem Anti-Cancer Agents 4(6):491-508
25. De Medina P, Payre BL, Bernad J, Bosser I, Pipy B, Silvente-Poirot S, Favre G, Faye JC, Poirot M (2004b) Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells. J Pharmacol Exp Ther 308:1165-1173
26. De Ponti F, Poluzzi E, Montanaro N (2000) QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol 56:1-18
27. Díaz M (1996) Volume-activated chloride channels in neuroblastoma cells are blocked by the antiestrogen toremifene. Cell Mol Neurobiol 16(3):403-409
28. Díaz M (1999) Modulation of Maxi Cl-channels by oestrogens and antioestrogens. J Physiol 517 P: 7S
29. Díaz M, Bahamonde MI, Lock H, Muñoz F, Hardy SP, Posas F, Valverde MA (2001) Okadaic acid-sensitive activation of Maxi Cl-channels by triphenylethylene antiestrogens in C1300 neuroblastoma cells. J Physiol 536(1):79-88
30. Díaz M (2002) Triphenylethylene antiestrogen-induced acute relaxation of mouse duodenal muscle. Possible involvement of calcium channels. Eur J Pharmacol 445:257-266
31. Dick GM, Hunter AC, Sanders KM (2002) Ethylbromide tamoxifen, a membrane impermeant antiestrogen, activates smooth muscle calcium-activated largeconductance potassium channels from the extracellular side. Mol Pharmacol 61(5):1105-1113
32. + currents. Br J Pharmacol 127:1819-1831
33. Dick GM, Rossow CF, Smirnov S, Horowitz B, Sanders KM (2001) Tamoxifen activates smooth muscle BK channels through the regulatory beta 1 subunit. J Biol Chem 276:34594-34599
34. Eisen SF, Brown HA (2002) Selective estrogen receptor (ER) modulators differentially regulate phospholipase D catalytic activity in ER-negative breast cancer cells. Mol Pharmacol 62(4):911-920
35. Engelke M, Tykhonova S, Zorn-Kruppa M, Diehl H (2002) Tamoxifen induces changes in the lipid composition of the retinal pigment epithelium cell line D407. Pharmacol Toxicol 91(1):13-21
36. Falkenstein E, Tillmann HC, Christ M, Feuring M, Wehling M (2000) Multiple actions of steroid hormones-a focus on rapid, nongenomic effects. Pharmacol Rev 52:513-556
37. Fanidi A, Courion-Guichardaz C, Fayard JM, Pageaux JF, Laugier C (1989) Effects of tamoxifen, tamoxifen metabolites, and nafoxidine on adenosine 3', 5'-monophosphate phosphodiesterase: correlations with growth inhibitory activities but not estrogen receptor affinities. Endocrinology 125:1187-1193
38. Fernandez A, Cantabrana B, Hidalgo A (1993) Estrogen and antiestrogen non-genomic effect in rat uterus contraction in calcium-free solution. Gen Pharmacol 24(2):391-395
39. Figtree G, Webb C, Collins P (1999) Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation 100:1095-1101
40. Figtree G, Webb C, Collins P (2000) Tamoxifen acutely relaxes coronary arteries by an endothelium, nitric oxide and estrogen receptor-dependent mechanism. J Pharmacol Exp Ther 295:519-523
41. Fisher B, Redmond C, Brown A, Wickerham DL, Wolmark N, Allegra J, Escher G, Lippman M, Savlov E, Wittliff J, et al. (1983) Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1(4):227-241
42. Fiucci G, Czarny M, Lavie Y, Zhao D, Berse B, Blusztajn JK, Liscovitch M (2000) Changes in phospholipase D isoform activity and expression in multidrug-resistant human cancer cells. Int J Cancer 85:882-888
43. Foster DA, Xu L (2003) Phospholipase D in cell proliferation and cancer. Mol Cancer Res 1(11):789-800
44. Friedman ZY (1994) The antitumor agent tamoxifen inhibits breakdown of polyphosphoinositides in GH4C1 cells. J Pharmacol Exp Ther 271(1):238-245
45. Gelband CH, Greco PG, Martens JR (1996) Voltage-dependent chloride channels: invertebrates to man. J Exp Zool 275(4):277-282
46. Gerner EW (1992) Ocular toxicity of tamoxifen. Ann Ophthalmol 21:420-423
47. Gonzalez-Perez J, Crespo MJ (2003) Acute effects of toremifene on the vasculature of intact and menopause-induced rats. Vascul Pharmacol 40(4):205-211
48. Greenberg DA, Carpenter CL, Messing RO (1987) Calcium channel antagonist properties of the antineoplastic antiestrogen tamoxifen in the PC12 neurosecretory cells. Cancer Res 47:70-74
49. Hardcastle IR, Rowlands MG, Houghton J, Parr IB, Potter GA, Jarman M, Edwards KJ, Laughton CA, Trent JO, Neidle S (1995) Rationally designed analogues of tamoxifen with improved calmodulin antagonism. J Med Chem 38:241-248
50. Hardy SP, Valverde MA (1994) Novel plasma membrane action of estrogen and antiestrogens revealed by their regulation of a large conductance chloride channel. FASEB J 8(10):760-765
51. Hardy SP, De Felipe C, Valverde MA (1998) Inhibition of voltage-gated cationic channels in rat embryonic hypothalamic neurones and C1300 neuroblastoma cells by triphenylethylene antioestrogens. FEBS Lett 434(3):236-240
52. He J, Kargacin ME, Kargacin GJ, Ward CA (2003) Tamoxifen inhibits Na+ and K+ currents in rat ventricular myocytes. Am J Physiol 285(2):H661-H668
53. Hiemke C, Ghraf R (1984) Interaction of non-steroidal antiestrogens with dopamine receptor binding. J Steroid Biochem 21:663-667
54. Holleran AL, Lindenthal B, Aldaghlas TA, Kelleher JK (1998) Effect of tamoxifen on cholesterol synthesis in HepG2 cells and cultured rat hepatocytes. Metabolism 47(12):1504-1513
55. Horgan K, Cooke E, Hallett MB, Mansel RE (1986) Inhibition of protein kinase C mediated signal transduction by tamoxifen: importance for antitumour activity. Biochem Pharmacol 35(24):4463-4465
56. Jordan VC, Murphy CS (1990) Endocrine pharmacology of antiestrogens as antitumor agents. Endocr Rev 11(4):578-610
57. Kahl CR, Means AR (2003) Regulation of cell cycle progression by calcium/calmodulindependent pathways. Endocr Rev 24:719-736
58. Kedjouar B, De Medina P, Oulad-Abdelghani M, Payre B, Silvente-Poirot S, Favre G, Faye JC, Poirot M (2004) Molecular characterization of the microsomal tamoxifen binding site. J Biol Chem 279(32):34048-34061
59. Kim HP, Lee JY, Jeong JK, Bae SW, Lee HK, Jo I (1999) Nongenomic stimulation of nitric oxide release by estrogen is mediated by estrogen receptor alpha localized in caveolae. Biochem Biophys Res Commun 263(1):257-262
60. Kiss Z (1994) Tamoxifen stimulates phospholipase D activity by an estrogen receptorin dependent mechanism. FEBS Lett 355:173-177
61. Kroeger EA, Brandes LJ (1985) Evidence that tamoxifen is a histamine antagonist. Biochem Biophys Res Commun 131(2):750-755
62. Lam HY (1984) Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem Biophys Res Commun 118:27-32
63. La Porte DC, Wierman BM, Store DR (1980) Calcium-induced exposure of a hydrophobic surface on calmodulin. Biochemistry 19:3814-3819
64. Lazier CB, Bapat BV (1988) Antiestrogen binding sites: general and comparative properties. J Steroid Biochem 4 B: 665-669
65. Levine L (2003a) Does the release of arachidonic acid from cells play a role in cancer chemoprevention? FASEB J 17(8):800-802
66. Levine L (2003b) Tamoxifen stimulates arachidonic acid release from rat liver cells by an estrogen receptor-independent, non-genomic mechanism. BMC Cancer 3(1):24
67. Li J, Xu LZ, Yao JJ, Guo WJ, Xia P, Chen Y (2001a) Reversal effects of droloxifene on multidrug resistance in adriamycin-resistant K562 cell line. Acta Pharmacol Sin 22(11):1023-1027
68. Li Z, Joyal JL, Sacks BD (2001b) Calmodulin enhances the stability of the estrogen receptor. J Biol Chem 276:17354-17360
69. Lien EA, Solheim E, Ueland PM (1991) Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 51:4837-4844
70. Ling V (1997) Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 40 (Suppl): S3-S8
71. Lipton A, Vinijsanun A, Martin L (1984) Acute inhibition of rat myometrial responses to oxytocin by tamoxifen stereoisomers and oestradiol. J Endocrinol 103(3):383-388
72. Lipton A (1987) The anti-oestrogen tamoxifen is a calcium antagonist in perfused rat mesentery. Cancer Chemother Pharmacol 20:125-127
73. Liu XK, Katchman A, Ebert SN, Woosley RL (1998) The antiestrogen tamoxifen blocks the delayed rectifier potassium current, IKr, in rabbit ventricular myocytes. J Pharmacol Exp Ther 287:877-883
74. Lopes M C F, Vale M G P, Carvalho AP (1990) Ca2+-dependent binding of tamoxifen to calmoduline isolated from bovine brain. Cancer Res 50:2753-2758
75. Lucci A, Giuliano AE, Han TY, Dinur T, Liu YY, Senchenkov A, Cabot MC (1999) Ceramide toxicity and metabolism differ in wild-type and multidrug-resistant cancer cells. Int J Oncol 15(3):535-540
76. +/Ca2 + exchange of brain cortex membranes. Biochem Pharmacol 40:1877-1884
77. Mansouri A, Henle KJ, Nagle WA (1992) Multidrug resistance: prospects for clinical management. SAAS Bull Biochem Biotechnol 5:48-52
78. Marrero-Alonso J, García Marrero B, Gomez T, Diaz M (2005) Functional inhibition of intestinal and uterine muscles by non-permeant triphenylethylene derivatives. Eur J Pharmacol (in press)
79. Mehta RR, Das Gupta TK (1987) Antiestrogen binding sites in microsomal fractions of malignant and nonmalignant human breast tissues. Breast Cancer Res Treat 9(1):61-67
80. Mesange F, Sebbar M, Capdevielle J, Guillemot JC, Ferrara P, Bayard F, Poirot M, Faye JC (2002) Identification of two tamoxifen target proteins by photolabeling with 4-(2-morpholinoethoxy) benzophenone. Bioconjug Chem 13(4):766-772
81. Nadal A, Díaz M, Valverde MA (2001) The estrogen trinity: membrane, cytosolic, and nuclear effects. News Physiol Sci 16:251-255
82. Nishizuka Y (1992) Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258:607-614
83. Noh DY, Ahn SJ, Lee RA, Park IA, Kim JH, Suh PG, Ryu SH, Lee KH, Han JS (2000) Overexpression of phospholipase D1 in human breast cancer tissues. Cancer Lett 161:207-214
84. O'Brian CA, Liskamp RM, Solomon DH, Weinstein IB (1986) Inhibition of protein kinase C by tamoxifen. Cancer Res 45:2462-2465
85. O'Brian CA, Ward NE, Anderson BW (1988) Role of specific interactions between protein kinase C and triphenylethylenes in inhibition of the enzyme. J Natl Cancer Inst 80(20):1628-1633
86. Palmer R M J, Ashton DS, Moncada S (1988) Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333:664-666
87. Patterson AJ, Henrie-Olson J, Brenner R (2002) Vasoregulation at the molecular level: a role for the beta1 subunit of the calcium-activated potassium (BK) channel. Trends Cardiovascul Med 12(2):78-82
88. Pavlidis NA, Petris C, Briassoulis E, Klouvas G, Psilas C, Rempapis J, Petroutsos G (1992) Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity: a prospective study of 63 patients. Cancer 69(12):2961-2964
89. Pollack IF, Da Rosso RC, Robertson PL, Jakacki RL, Mirro JR, Blatt J, Nicholson S, Packer RJ, Allen JC, Cisneros A, Jordan VC (1997) A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood. Clin Cancer Res 3:1109-1115
90. Rao US, Fine RL, Scarborough GA (1994) Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol 48(2):287-292
91. Rapoport RM, Draznin MB, Murad F (1983) Endothelium-dependent relaxation in rat aorta may be mediated through cyclic GMP-dependent protein phosphorylation. Nature 306:174-176
92. Ratz PH, MacCammon KA, Altstatt D, Blackmore PF, Shenfeld OZ, Schlossberg SM (1999) Differential effects of sex hormones and phystoestrogens on peak and steady state contractions in isolated rabbit detrusor. J Urol 162:1821-1828
93. Rowlands MG, Parr IB, McCague R, Jarman M, Goddard PM (1990) Variation of the inhibition of calmodulin dependent cyclic AMP phosphodiesterase amongst analogues of tamoxifen: correlations with cytotoxicity. Biochem Pharmacol 40:283-289
94. Sartor P, Vacher P, Mollard P, Dufy B (1988) Tamoxifen reduces calcium currents in a clonal pituitary cell line. Endocrinology 123:534-540
95. Simoncini T, Genazzani AR (2000) Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase. J Clin Endocrinol Metab 85(8):2966-2969
96. Simoncini T, Genazzani AR, Liao JK (2002a) Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation 105:1368-1373
97. Simoncini T, Varone G, Fornari L, Mannella P, Luisi M, Labrie F, Genazzani AR (2002b) Genomic and nongenomic mechanisms of nitric oxide synthesis induction in human endothelial cells by a fourth-generation selective estrogen receptor modulator. Endocrinology 143(6):2052-2061
98. + currents by tamoxifen. J Memb Biol 181:125-135
99. Song J, Standley PR, Zhang F, Joshi D, Gappy S, Sowers JR, Ram JL (1996) Tamoxifen (estrogen antagonist) inhibits voltage-gated calcium current and contractility in vascular smooth muscle from rats. J Pharmacol Exp Ther 277:1444-1453
100. Sutherland RL, Murphy LC, San Foo M, Green MD, Whybourne AM, Krozowski ZS (1980) High-affinity anti-oestrogen binding site distinct from the oestrogen receptor. Nature 288(5788):273-275
101. Chen TC, Su S, Fry D, Liebes L (2003) Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma. Cancer 97:2363-2373
102. Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP, Panella TJ, Jordan VC, Fine RL (1992) High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: Phase I trial in combination with vinblastine. J Natl Cancer Inst 84:1811-1816
103. Tsang SY, Yao X, Essin K, Wong CM, Chan FL, Gollasch M, Huang Y (2004) Raloxifene relaxes rat cerebral arteries in vitro and inhibits L-type voltage-sensitive Ca2+ channels. Stroke 35(7):1709-1714
104. Uchida N, Okamura S, Kuwano H (1999) Phospholipase D activity in human gastric carcinoma. Anticancer Res 19:671-675
105. Valverde MA, Hardy SP, Diaz M (2002) Activation of Maxi Cl-channels by antiestrogens and phenothiazines in NIH3T3 fibroblasts. Steroids 67(6):439-445
106. Valverde MA, Mintenig GM, Sepulveda FV (1993) Differential effects of tamoxifen and I-on three distinguishable chloride currents activated in T84 intestinal cells. Pflügers Arch 425(5-6):552-554
107. Valverde MA, Rojas P, Amigo J, Cosmelli D, Orio P, Bahamonde MI, Mann G, Vergara C, Latorre R (1999) Acute activation of Maxi-K channels (Hslo) by estradiol binding to the β subunit. Science 285:1929-1931
108. Watts CK, Sutherland RL (1987) Studies on the ligand specificity and potential identity of microsomal antiestrogen-binding sites. Mol Pharmacol 31:541-551
109. Weber G, Shen F, Yang H, Prajda N, Li W (1999) Regulation of signal transduction activity in normal and cancer cells. Anticancer Res 19(5A):3703-3709
110. Westermann AM, Havik E, Postma FR, Beijnen JH, Dalesio O, Moolenaar WH, Rodenhuis S (1998) Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol 9:437-442
111. Wiseman H, Cannon M, Arnstein HR, Barlow DJ (1992a) The structural mimicry of membrane sterols by tamoxifen: evidence from cholesterol coefficients and molecularmodelling for its action as a membrane anti-oxidant and an anti-cancer agent. Biochim Biophys Acta 1138(3):197-202
112. Wiseman H, Quinn P, Halliwell B (1993) Tamoxifen and related compounds decrease membrane fluidity in liposomes: mechanism for the antioxidant action of tamoxifen and relevance to its anticancer and cardioprotective actions? FEBS Lett 330(1):53-56
113. Wiseman H, Smith C, Halliwell B, Cannon M, Arnstein HR, Lennard MS (1992b) Droloxifene (3-hydroxytamoxifen) has membrane antioxidant ability: potential relevance to its mechanism of therapeutic action in breast cancer. Cancer Lett 66(1):61-68
114. Wiseman H (1994) Tamoxifen: new membrane-mediated mechanisms of action and therapeutic advances. Trends Pharmacol Sci 15(3):83-89
115. Zhang JJ, Jacob T J C, Valverde MA, Hardy SP, Mintenig GM, Sepúlveda FV, Gill DR, Hyde SC, Trezise A E O, Higgins CF (1994) Tamoxifen blocks chloride channels: a possible mechanism for cataract formation. J Clin Invest 94:1690-1697
116. Zhao Y, Ehara H, Akao Y, Shamoto M, Nakagawa Y, Banno Y, Deguchi T, Ohishi N, Yagi K, Nozawa Y (2000) Increased activity and intranuclear expression of phospholipase D2 in human renal cancer. Biochem Biophys Res Commun 278:140-143
117. Resch U, Mellauner V, Budinsky A, Sinzinger H (2004) Inhibition of low-density lipoprotein and high-density lipoprotein oxidation by raloxifene. J Womens Health (Larchmt) 13(4):404-11